Endothelin Receptor Antagonists: New Hope for Renal Protection? - Wikidata - awgldk - TriplyDB

Endothelin Receptor Antagonists: New Hope for Renal Protection?

Endothelin Receptor Antagonists: New Hope for Renal Protection?

http://www.wikidata.org/entity/Q38525983

about

Endothelin-1 Immunoreactivity and its Association with Intramedullary Hemorrhage and Myelomalacia in Naturally Occurring Disk Extrusion in Dogs Atrasentan for the treatment of diabetic nephropathy.

P2860

Q37391757-B0F34C90-FF9B-49D4-AF35-248DF7F37DD7 Q38806647-23E27E23-EAEA-4A58-97AF-DE38D7266216

P2860

Endothelin Receptor Antagonists: New Hope for Renal Protection?

http://www.wikidata.org/entity/Q38525983

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Endothelin Receptor Antagonists: New Hope for Renal Protection?

@en

type

label

Endothelin Receptor Antagonists: New Hope for Renal Protection?

@en

prefLabel

Endothelin Receptor Antagonists: New Hope for Renal Protection?

@en

P1433

Q38525983-AF90FB80-1E28-4426-A8B4-D92E726F3AC8

P1476

Q38525983-B36E4859-67FB-4728-999D-ADC6AC8CA2BC

P2093

Q38525983-146D2758-8579-409F-915E-586B46BA8980

Q38525983-74680FF6-7E2F-455D-BACB-DA60D3E91B53

Q38525983-EE5B47C9-F1BE-409E-A0AB-3F4F0E97A915

P2860

Q38525983-0110CA05-7134-44A2-8B63-8D454ACAD40F

Q38525983-08401AF5-D70D-4A52-AA4C-ADE56AFEC7C9

Q38525983-171BC198-799C-4070-BD3A-7E569E1433EE

Q38525983-17E68DD0-ED23-4177-82B9-3F915CDD1B0E

Q38525983-17F8C67A-1A07-4CB0-9DC8-882B57478B8C

Q38525983-1997F4BF-6C5F-40DA-A434-377B25EBBF06

Q38525983-261C9BB0-8A62-4663-9B97-F3EF4EDEA976

Q38525983-26B4AAB0-369B-48E0-8E39-E68B23B6B58A

Q38525983-285445AE-A490-41BF-9A0E-07E573A89B0B

Q38525983-2DDB1698-FCAC-423A-AAEB-DE94AC24305B

P2888

Q38525983-F99E28C4-A3F8-4EA6-AD1B-77291EEBD576

P304

Q38525983-814066B1-E8B1-4779-8F4C-396CF0CE9081

P31

Q38525983-45F55CE4-6200-420E-B8B3-0A7400529B00

P356

Q38525983-56CD7742-09E7-48A3-AA6B-961DC64715AC

P433

Q38525983-FDDE9952-EEE2-4775-A8CC-752733889829

P478

Q38525983-32208233-EBA3-4CC1-BFA4-4711A9E32C45

P577

Q38525983-6CF47312-8456-4F2E-9CFF-098300F3E5CD

P6179

Q38525983-8DB275F1-3F2A-4ACD-A790-9BB261B74CB8

P698

Q38525983-0B2EE9BE-F0B4-4845-8B0C-9E38EE165670

P356

S11906-015-0568-7

P1433

Current Hypertension Reports

P1476

Endothelin Receptor Antagonists: New Hope for Renal Protection?

@en

P2093

Donald E Kohan

http://www.w3.org/2001/XMLSchema#string

Ranjit Singarayer

http://www.w3.org/2001/XMLSchema#string

Sheldon Tobe

http://www.w3.org/2001/XMLSchema#string

P2860

Avosentan reduces albumin excretion in diabetics with macroalbuminuria

Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

Avosentan for overt diabetic nephropathy.

Progression, remission, regression of chronic renal diseases.

Role of endothelin-1 in hypertension and vascular disease.

Chronic kidney disease: global dimension and perspectives.

Endothelin and endothelin antagonists in chronic kidney disease.

Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?

Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.

P2888

s11906-015-0568-7

P304

57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11906-015-0568-7

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1026849723

http://www.w3.org/2001/XMLSchema#string

P698

26068660

http://www.w3.org/2001/XMLSchema#string